First results of triple‐modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with Stage IIB, III, and IVA cervical carcinoma

Cancer (Impact Factor: 4.89). 08/2005; 104(4):763 - 770. DOI: 10.1002/cncr.21128
Source: PubMed


Patients with advanced cervical carcinoma are treated routinely with radiotherapy and cisplatin-containing chemotherapy. It has been shown that hyperthermia can improve the results of both radiotherapy and cisplatin. In the current study, the feasibility and efficacy of the combination of all three modalities was studied in previously untreated patients with cervical carcinoma.METHODS
Patients with advanced cervical carcinoma were registered prospectively in the U.S., Norway, and the Netherlands. External-beam radiotherapy and brachytherapy were administered for a biologically effective dose ≥ 86.7 gray. At least 4 courses of weekly cisplatin (40 mg/m2) and 4 sessions of weekly locoregional hyperthermia were added to radiotherapy.RESULTSSixty-eight patients with a median age of 45 years were enrolled. Full-dose radiotherapy was delivered to all patients according to plan. At least 4 courses of chemotherapy were received by 97% of patients, and at least 4 courses of hyperthermia treatment were received by 93% of patients. Toxicity was fully comparable to that described for chemoradiotherapy alone, and the median total treatment time was 45 days. Complete remission was achieved by 61 patients (90%). After a median follow-up of 538 days, 74% of patients remained alive without signs of recurrence, and the overall survival rate was 84%.CONCLUSIONS
The combination of full-dose radiotherapy, chemotherapy, and hyperthermia was feasible and effective in a multicenter international setting among patients with advanced cervical carcinoma. A Phase III study comparing this novel triplet with standard chemoradiation, designed to show at least a 15% improvement in overall survival, has been launched. Cancer 2005. © 2005 American Cancer Society.

Download full-text


Available from: Ellen L Jones,
  • Source
    • "The cytotoxicity of these drugs is synergized by heat, but the timing between the chemotherapy and HT may not have been adequate for the present patient. For the concomitant use of radiotherapy, chemotherapy and HT for the treatment of patients with cervical carcinoma, Westermann et al (19) advised that chemotherapy and HT should be administered concurrently, preferentially 1 h, but no more than 6 h, prior to radiotherapy. The optimal sequence of the administration of these three therapeutic modalities for the treatment of LMS has yet to be elucidated. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Advanced uterine leiomyosarcoma (LMS) is a rare and extremely aggressive disease. In patients with advanced and unresected uterine LMS, multidisciplinary therapy is the best treatment option, although no consensus exists on the efficacy of the treatment. The present study describes the case of a 41-year-old female who underwent laparotomy due to a large uterine tumor. Exploratory laparotomy revealed a large tumor that had extended from the pelvic wall to the outside of the pelvis and then invaded the colon. Large residual tumors remained present in the pelvis following suboptimal debulking surgery. Subsequent to surgery, the patient was treated with adjuvant radiotherapy, followed by chemotherapy with regional whole pelvis hyperthermia (HT). Computed tomography revealed stable disease prior and subsequent to combination treatment. While treatment was being administered for third/fourth-degree burns and subcutaneous fatty necrosis, the patient developed multi-organ failure and succumbed. The present case report describes the potential for using a combination of chemotherapy, HT and radiotherapy in patients with LMS. The development of an effective protocol is required for the administration of chemotherapy, HT and radiotherapy in patients with advanced unresected LMS.
    Oncology letters 08/2014; 8(2):637-641. DOI:10.3892/ol.2014.2193 · 1.55 Impact Factor
  • Source
    • "These studies, and the low toxicity caused by ATO in our experience, suggested that a regimen consisting of radiation, ATO, and local hyperthermia may be more effective than the already clinically used cisplatin-based combination therapy. Phase III clinical studies using thermoradiotherapy with cisplatin have begun [16]. This clinical trial was expanded to a multicenter, international trial against cervical cancer due to the encouraging initial results. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Our previous studies demonstrated arsenic trioxide- (ATO-) induced selective tumor vascular disruption and augmentation of thermal or radiotherapy effect against solid tumors. These results suggested that a trimodality approach of radiation, ATO, and local hyperthermia may have potent therapeutic efficacy against solid tumors. Here, we report the antitumor effect of hypofractionated radiation followed by ATO administration and local 42.5 °C hyperthermia and the effects of cisplatin and thermoradiotherapy. We found that the therapeutic efficacy of ATO-based thermoradiotherapy was equal or greater than that of cisplatin-based thermoradiotherapy, and marked evidence of in vivo apoptosis and tumor necrosis were observed in ATO-treated tumors. We conclude that ATO-based thermoradiotherapy is a powerful means to control tumor growth by using vascular disruption to augment the effects of thermal and radiation therapy.
    Journal of Oncology 01/2012; 2012(6):934918. DOI:10.1155/2012/934918
  • Source
    • "The latter approach, hyperthermia, is used as sole agent or as an adjuvant therapy together with chemotherapy and radiotherapy [2], utilizing magnetic fields [3] and NIR lasers [4]. Despite promising results, optical energy sources are mainly limited to the treatment of subcutaneous tumours. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The major problem of current drug-based therapy is selectivity. As in other areas of science, a combined approach might improve the situation decisively. The idea is to use the pro-drug principle together with an alternating magnetic field as physical stimulus, which can be applied in a spatially and temporarily controlled manner. As a proof of principle, the neutral hydrolysis of aspirin in physiological phosphate buffer of pH 7.5 at 40 degrees C was chosen. The sensor and actuator system is a commercially available gold nanoparticle (NP) suspension which is approved for animal usage, stable in high concentrations and reproducibly available. Applying the alternating magnetic field of a conventional NMR magnet system accelerated the hydrolysis of aspirin in solution.
    Nanoscale Research Letters 08/2009; 4(8):854-857. DOI:10.1007/s11671-009-9332-8 · 2.78 Impact Factor
Show more